文献速递药物不良反应与药物警戒

威尔士引入国家报告指标后黄卡疑似药品不良反应报告变化

Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator.
PubMed 文献 · Br J Clin Pharmacol · 2022-04-07

该研究评估威尔士2014年4月引入国家报告指标(NRI)对黄卡疑似药品不良反应报告率的影响。威尔士其他群体报告数无相应变化。

要点

  • NRI实施后威尔士全科医生黄卡报告量显著增加,且持续至2018-19年。
  • 威尔士其他报告群体的黄卡提交数未见伴随性变化。

核心结论

  • 引入国家报告指标与威尔士全科医生黄卡提交数量显著增加相关。
  • 全科医生报告率在NRI持续实施期间逐年增加至2018-19年。
  • 威尔士卫生委员会其他群体的报告率未见同步变化。

研究设计与样本

  • 基于英国药品和健康产品管理局黄卡报告数据的比较研究。
  • 比较威尔士与英格兰全科医生及其他报告群体在2014-15和2015-16财年与2013-14控制期的报告数。

主要发现

  • 威尔士全科医生黄卡提交数在控制期、研究期1和研究期2分别为271、665和870。
  • 研究期1和2较控制期分别增加145%和221%。
  • 威尔士其他群体各期黄卡提交数分别为906、795和947。

临床怎么用

  • 提示国家层面报告指标可能提升全科医生药品不良反应上报积极性。
  • 针对特定报告群体的激励措施需关注其对报告数量的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to assess the impact of a National Reporting Indicator (NRI) on rates of reporting of suspected adverse drug reactions using the Yellow Card scheme following the introduction of the NRI in Wales (UK) in April 2014. METHODS: Yellow Card reporting data for general practitioners and other reporting groups in Wales and England for the financial years 2014-15 (study period 1) and 2015-16 (study period 2) were obtained from the Medicines and Healthcare Products Regulatory Agency and compared with those for 2013-14 (pre-NRI control period). RESULTS: The numbers of Yellow Cards submitted by general practitioners in Wales were 271, 665 and 870 in the control period, study period 1 and study period 2, respectively. This is equivalent to an increase of 145% in study period 1 and 221% in study period 2 compared with the 12-month control period (2013-14). Corresponding increases in England were 17% and 37%, respectively (P < .001 chi-squared test). The numbers of Yellow Cards submitted by other groups in Wales were 906, 795 and 947 in each of the study periods. CONCLUSIONS: Introduction of the NRI corresponded with a significant increase in the number of Yellow Cards submitted by general practitioners in Wales. General practitioner reporting rates continued to increase year on year through to 2018-19 with the NRI still in place. No concomitant change was found in reporting rates by other groups in the health boards in Wales.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Deslandes PN, Bracchi R, Jones K, et al. Changes in suspected adverse drug reaction reporting via the yellow card scheme in Wales following the introduction of a National Reporting Indicator. Br J Clin Pharmacol. 2022. PMID: 35322450. doi:10.1111/bcp.15326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。